LGC launches stability testing service

Adding to the drug development services delivered from its Fordham, Cambridgeshire site, LGC has announced a stability testing service, said to enable continuous recording and monitoring of essential data on the impact of environmental factors such as temperature and humidity on the quality of a pharmaceutical product.

LGC provides on-site stability storage at a range of ICH (International Conference on Harmonisation) and non-standard conditions for long-term stability, accelerated stability and photostability assessment of clinical trial materials, actives and finished products. According to LGC, the conditions in the stability chambers are continuously monitored by automated systems and benefit from full back-up power supplies. With method development, validation and cGMP analytical testing capabilites, LGC aims to manage stability programmes to provide an integrated service to meet requirements.

Jeremy Cook, managing director, laboratory and managed services, LGC, said: “We are delighted to be able to offer stability testing, which further extends our drug development portfolio. In doing so, we can establish either a retest period for a drug substance or a shelf life and recommended storage conditions for a manufactured product, which are all essential to minimising market risk and helping us towards our vision of using our science for a safer world.”

With the acquisition of the leading bioanalytical business from Quotient Bioresearch in December 2012, LGC now has more than 50 years’ experience in high-integrity analytical science and expertise spanning small and large molecules, biomarkers, molecular biology and microbiology.  

LGC, www.lgcgroup.com.